Decoy Therapeutics
DCOY
1 hedge funds and large institutions have $1M invested in Decoy Therapeutics in 2019 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
44% more capital invested
Capital invested by funds: $697K → $1M (+$304K)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$318K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$88K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$29K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 4 |
Primecap Management
Pasadena,
California
|
-$13K |
| 5 |
TI
Telemetry Investments
New York
|
-$5K |
DCOY Hedge Fund Activity: Q1 2019 in Review
1 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2019, worth a combined $1M — up 44% from $697K a quarter earlier.
Fund positioning in DCOY was balanced in Q1 2019: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $318K. The largest seller was Ameriprise, cutting an estimated $88K.
- 1 institutional investor held Decoy Therapeutics (DCOY) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $1M of Decoy Therapeutics stock for Q1 2019, up 44% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q1 2019 and 0 closed out.
- The largest Decoy Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $318K added.
- The largest Decoy Therapeutics seller in Q1 2019 was Ameriprise, an estimated $88K sold.
Based on aggregated 13F filings for Q1 2019.